- Home
- PSNL vs HQL Comparison
PSNL vs HQL Comparison
Compare PSNL & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- HQL
- Stock Information
- Founded
- PSNL 2011
- HQL 1992
- Country
- PSNL United States
- HQL United States
- Employees
- PSNL N/A
- HQL N/A
- Industry
- PSNL Medical Specialities
- HQL Investment Managers
- Sector
- PSNL Health Care
- HQL Finance
- Exchange
- PSNL Nasdaq
- HQL Nasdaq
- Market Cap
- PSNL 460.7M
- HQL 368.7M
- IPO Year
- PSNL 2019
- HQL N/A
- Fundamental
- Price
- PSNL $3.45
- HQL $12.29
- Analyst Decision
- PSNL Strong Buy
- HQL
- Analyst Count
- PSNL 5
- HQL 0
- Target Price
- PSNL $7.80
- HQL N/A
- AVG Volume (30 Days)
- PSNL 883.3K
- HQL 120.9K
- Earning Date
- PSNL 05-07-2025
- HQL 01-01-0001
- Dividend Yield
- PSNL N/A
- HQL 11.56%
- EPS Growth
- PSNL N/A
- HQL N/A
- EPS
- PSNL N/A
- HQL 0.79
- Revenue
- PSNL $84,614,000.00
- HQL N/A
- Revenue This Year
- PSNL N/A
- HQL N/A
- Revenue Next Year
- PSNL $27.78
- HQL N/A
- P/E Ratio
- PSNL N/A
- HQL $17.08
- Revenue Growth
- PSNL 15.15
- HQL N/A
- 52 Week Low
- PSNL $1.14
- HQL $11.34
- 52 Week High
- PSNL $7.20
- HQL $14.37
- Technical
- Relative Strength Index (RSI)
- PSNL 39.63
- HQL 26.87
- Support Level
- PSNL $3.33
- HQL $12.90
- Resistance Level
- PSNL $3.65
- HQL $13.30
- Average True Range (ATR)
- PSNL 0.25
- HQL 0.23
- MACD
- PSNL 0.03
- HQL -0.04
- Stochastic Oscillator
- PSNL 19.17
- HQL 3.81
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.